Patient P-03103
Therapy response
Favorable
Tolerance
Favorable
GI state
Stable
Inflammatory state
Improving
Nutritional resilience
Stable
Discontinuation risk
59%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 ONX-7 started — Baseline state S14
- Day 39 NP-02 recommended — Dietary Support Protocol NP-02
- Day 40 Patient accepted — Started NP-02 in the companion
- Day 50 No meaningful change — Dietary Support Protocol NP-02
- Day 66 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 71 GI-04 recommended — GI Support Protocol GI-04
- Day 72 Patient accepted — Started GI-04 in the companion
- Day 80 GI symptom burden −36% vs expected — GI Support Protocol GI-04
- Day 86 Tolerance state changed — Unstable → Improving
What changed?
Trajectory began diverging from predicted response on Day 66.
Primary contributors, last 14 days
- Treatment adherence-21
- Inflammatory activity-6
- GI instability+4
- Toxicity-3
- Nutritional resilience-2
What helped?
- Dietary Support Protocol NP-02Day 39Result: no meaningful change
- GI Support Protocol GI-04Day 71Result: symptom burden −36%
LIFE OS recommendation
Clinician Review CR-01
83%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 100% showed improvement
- median effect visible after 5 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Inflammatory signalling ↓85
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 42
- WearableHRV 29 ms, trending down
- Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 24/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Mucosal barrier integrity ↓70
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- WearableSleep 5.7 h, below personal baseline
- Autonomic recovery ↓45
- WearableResting HR 77 bpm
- WearableShort sleep window
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Normal metabolizerExpected exposure
Microbiome
Shannon diversity 2.6 · butyrate capacity 24/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisHigh
- Bifidobacterium longumNormal
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 33 ms
- Sleep
- 5.5 h
- Steps
- 6,600
- Resting HR
- 74 bpm
Daily log: GI score 44, nutritional resilience 46, adherence 62.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- Keep the current walking rhythm
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-03365 | 47% | S14 | NP-02 | improved | 46 |
| P-03279 | 37% | S14 | GI-04 | improved | 57 |
| P-03289 | 37% | S03 | SC-12 | improved | 54 |
| P-03021 | 34% | S15 | — | — | 57 |
| P-03463 | 33% | S11 | GI-04 | no change | 55 |
| P-03031 | 32% | S16 | CR-01 | improved | 49 |
| P-03451 | 32% | S08 | — | — | 62 |
| P-03382 | 31% | S01 | GI-04 | improved | 56 |
| P-03444 | 31% | S17 | — | — | 62 |
| P-03465 | 31% | S17 | CR-01 | improved | 65 |
| P-03046 | 30% | S20 | GI-04 | no change | 53 |
| P-03123 | 30% | S14 | GI-04 | improved | 50 |